TLV receives a new assignment for precision medicine and advanced therapy drugs

15 June 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, is commissioned by the government to continue the ...

Read more →

Sweden's cost of medicines is increasing

15 June 2021 - Sweden's costs for pharmaceuticals have risen by approximately SEK 2 billion between 2019 and 2020.  ...

Read more →

The national health data registers are the way forward

17 May 2021 - The key to developing follow-up of medicines and medical technology products is the national health data registers, ...

Read more →

The National Audit Office's review can contribute to strengthening TLV's work

7 May 2021 - On 6 May, the National Audit Office published its report on the Government's and TLV's work ...

Read more →

Uncertain effect and high prices of precision medicine are challenging

3 May 2021 - In a report to the government, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, describes the most ...

Read more →

TLV reconsiders subsidy for eleven TNF alfa inhibitors included in the high-cost protection

30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection. ...

Read more →

Additional analysis of Luxturna in the treatment of visual impairment caused by hereditary eye disease

21 April 2021 - TLV has made a supplementary analysis to the previous evaluation of Luxturna, as Novartis has submitted new ...

Read more →

Health economic assessment of Qarziba in patients with high-risk neuroblastoma

21 April 2021 - TLV has produced a health economic assessment for the regions for the drug Qarziba (dinutuximab beta).  ...

Read more →

Health economic assessment of Darzalex in multiple myeloma

19 April 2021 - TLV has produced a health economic assessment for the regions for the drug Darzalex in combination with ...

Read more →

TLV subsidises melatonin for children and adolescents with ADHD

26 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, grants a subsidy for the drug Melatonin AGB ...

Read more →

Too high price for drugs for cystic fibrosis

25 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, says no to subsidising the drugs Kaftrio and Kalydeco ...

Read more →

Health economic assessment of Zolgensma in spinal muscular atrophy

12 March 2021 - TLV has produced a health economic assessment for the regions for Zolgensma (onasemnogene abeparvovec) in the treatment ...

Read more →

Discounting in economic evaluation of health care interventions: what about the risk term?

13 March 2021 - Results from economic evaluations of long-term outcomes are strongly dependent on the chosen discount rate.  ...

Read more →

TLV is tasked with reducing costs for medicines

16 February 2021 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency, TLV, to implement measures to reduce ...

Read more →

On the role of cost effectiveness thresholds in health care priority setting

25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...

Read more →